We have identified punicalagin as a PDIA3 inhibitor [33], and in a recent work [34] we provide evidence that PDIA3 inhibition offers a valid therapeutic treatment in glioblastoma, confirming the importance of identifying selective inhibitors. The gene discussed is PDIA3; the disease is glioblastoma.